The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March

The Oncology Institute, Inc. (NASDAQ: TOI), a leader in value-based community oncology, is set to participate in several healthcare investor conferences throughout March 2026. This engagement will feature key presentations from its executive team, aiming to enhance investor awareness and showcase the organization's commitment to advancing oncology care.

On March 9, 2026, Dr. Daniel Virnich, the CEO, will speak at the Jefferies Healthcare Services Innovation & Technology Summit in Miami, FL, from 11:30 a.m. to 12:00 p.m. ET. The same day, Rob Carter, the CFO, will present at the Leerink Global Healthcare Conference, also in Miami, from 3:00 p.m. to 3:30 p.m. ET. Both events will help highlight TOI's innovative approach to cancer care. Additionally, on March 16, the executive leadership team will present at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, where both Dr. Virnich and Rob Carter will share insights from 10:00 a.m. to 10:30 a.m. ET.

The presentations will be accessible via live webcasts and replays through the Investor Relations section of TOI’s website, offering broader access to shareholders and interested stakeholders.

Founded in 2007, The Oncology Institute is transforming oncology care by providing specialized, evidence-based medical services to approximately 1.9 million patients across over 100 clinics and affiliate locations in five states. By employing over 180 clinicians, TOI is pioneering advanced cancer treatment options in community settings, expanding access to high-quality oncology services that were once centralized in major hospital systems. This proactive approach emphasizes personalized, value-driven care while fostering innovation in the oncology landscape.

The Oncology Institute, Inc. (NASDAQ: TOI) is poised for a significant moment in March 2026, with its participation in multiple healthcare investor conferences. As a pioneer in value-based community oncology care, TOI's engagement in these events highlights its commitment to transparency and innovation in cancer care, making it a key player in the healthcare landscape.

Investors should take note of the timing and content of these presentations. Dr. Daniel Virnich, the CEO, and Rob Carter, the CFO, will both provide insights on March 9 and March 16, respectively. This increased visibility may attract attention from institutional and retail investors alike, potentially driving a bullish sentiment around TOI’s stock.

The focus of these conferences is expected to revolve around TOI's innovative approaches to cancer care, including their evidence-based treatment methods and the scalability of their community clinics. With over 100 locations and a patient base of approximately 1.9 million, TOI’s market presence is significant. Investors should consider how TOI’s model can lead to sustained revenue growth, especially as the demand for specialized cancer care continues to rise.

Furthermore, investors should pay attention to any strategic announcements regarding partnerships or new service offerings during these conferences. Such developments could enhance TOI’s competitive advantage and market share in the oncology sector.

While participating in these conferences carries inherent risks, it may also present a unique opportunity for investors to engage with a company that is not only dedicated to better patient outcomes but is also strategically positioning itself within a growing sector. Monitoring TOI’s presentations, coupled with broader market trends in healthcare investing, could provide valuable insights for prospective and current shareholders.